Aerie Pharmaceuticals Inc. (NASDAQ:AERI)’s share price traded down 3.9% during trading on Monday . The company traded as low as $17.38 and last traded at $17.44, with a volume of 150,890 shares. The stock had previously closed at $18.14.

A number of equities analysts have commented on the company. Cantor Fitzgerald assumed coverage on Aerie Pharmaceuticals in a research note on Thursday, June 2nd. They issued a “buy” rating and a $44.00 price objective on the stock. Zacks Investment Research raised Aerie Pharmaceuticals from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research note on Tuesday, July 12th. Brean Capital reissued a “buy” rating on shares of Aerie Pharmaceuticals in a research note on Tuesday, May 3rd. Finally, Canaccord Genuity reissued a “buy” rating on shares of Aerie Pharmaceuticals in a research note on Tuesday, May 3rd. Eight equities research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and a consensus price target of $42.50.

The stock’s market cap is $458.67 million. The stock’s 50-day moving average is $17.90 and its 200 day moving average is $16.01.

Aerie Pharmaceuticals (NASDAQ:AERI) last announced its quarterly earnings results on Monday, May 2nd. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by $0.08. On average, equities research analysts forecast that Aerie Pharmaceuticals Inc. will post ($2.69) EPS for the current fiscal year.

An institutional investor recently raised its position in Aerie Pharmaceuticals stock. Nationwide Fund Advisors increased its position in shares of Aerie Pharmaceuticals Inc. (NASDAQ:AERI) by 56.6% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 56,078 shares of the company’s stock after buying an additional 20,265 shares during the period. Nationwide Fund Advisors owned 0.21% of Aerie Pharmaceuticals worth $1,365,000 as of its most recent SEC filing.

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.